Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15539074 | 0.96 | GPR119 (0.57) | GPR119CHEK2HDAC1 | |
| SCHEMBL19610292 | 0.93 | GPR119 (0.54) | GPR119CHEK2KDM4EPKMALDH1A1 | |
| SCHEMBL12834985 | 0.90 | GPR119 (0.58) | GPR119CHEK2KDM4EPKMHDAC1 | |
| SCHEMBL2456170 | 0.89 | GPR119 (0.57) | GPR119CHEK2KDM4EPKMHDAC1 | |
| SCHEMBL213773 | 0.89 | GPR119 (0.57) | GPR119CHEK2KDM4EPKMHDAC1 | |
| SCHEMBL3256200 | 0.89 | GPR119 (0.57) | GPR119CHEK2KDM4EPKMHDAC1 | |
| SCHEMBL1769099 | 0.89 | GPR119 (0.57) | GPR119CHEK2KDM4EPKM | |
| SCHEMBL3249170 | 0.88 | KDM4E (0.61) | GPR119CHEK2KDM4EPKM | |
| SCHEMBL17078731 | 0.88 | GPR119 (0.56) | GPR119CHEK2KDM4EPKMHDAC1 | |
| SCHEMBL3096959 | 0.88 | GPR119 (0.67) | GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3668877-B1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CBR1 | GPR119 1811/4885CHEK2 2093/4885KDM4E 2680/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | GPR119 1/4885CHEK2 4794/4885KDM4E 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.